Vincristine

Drug Levels and Effects:




Summary of Use during Lactation:


Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.


Drug Levels:


Maternal Levels.

Relevant published information was not found as of the revision date.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


In a 4-month-old, neutropenia was probably caused by cyclophosphamide in a mother 9 days after the last of 6 weekly doses of 800 mg cyclophosphamide intravenously, 2 mg vincristine intravenously and daily doses of 30 mg of prednisolone orally. Neutropenia persisted at least 12 days and was accompanied by a brief episode of diarrhea.[1] The contribution of vincristine to the neutropenia cannot be determined.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


Alternate Drugs to Consider:


Dependent on the condition being treated.


References:


1. Amato D, Niblett JS. Neutropenia from cyclophosphamide in breast milk. Med J Aust. 1977;1:383-4.



Substance Identification:




Substance Name:

Vincristine

CAS Registry Number:

57-22-7

Drug Class:


  • Antineoplastic Agents


  • Administrative Information:




    LactMed Record Number:


    278


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.